INTRODUCTION
Persistent pulmonary hypertension of the newborn is commonly diagnosed with respiratory failure in neonates. [1] [2] [3] It is characterized by pulmonary hypertension and extrapulmonary right-to-left shunting across the foramen ovale and ductus arteriosus. Several studies have shown that inhaled nitric oxide is useful in reducing the use of extracorporeal membrane oxygenation. 1, [3] [4] [5] [6] However, there are only two other randomized control trials that have reported data on the long-term outcome of neonates treated with inhaled nitric oxide compared to neonates who did not receive treatment. 3, 7 The purpose of our study is to report on the 1 year outcome of neonates treated with inhaled nitric oxide compared to a group of neonates who did not receive nitric oxide.
METHODS

Study Subjects
As previously reported, 1 we studied 248 neonates born after more than 34 weeks' gestation, who were 4 days old or less, required assisted ventilation, and had an oxygenation index ([mean airway pressure Â FiO 2 Â 100]/PaO 2 ) of Z25. These neonates were required to have clinical or echocardiographic evidence of pulmonary hypertension without structural heart disease. Neonates were not eligible for the study if extracorporeal membrane oxygenation was urgently needed for refractory hypotension (mean blood pressure <35 Torr) or profound hypoxemia (partial pressure of arterial oxygen <30 Torr); or if they had a lethal congenital anomaly, significant bleeding diathesis, active seizures, or a history of severe asphyxia.
Study mechanics
The Institutional Review Board at each study site approved the study, and consent was obtained from the patients' parents or guardians. Study enrollment and randomization was described in our primary publication. 1 Criteria for the use of extracorporeal membrane oxygenation were: an oxygenation index >40 Torr in three of five measurements Z30 min apart; partial pressure of arterial oxygen <40 Torr for 2 hours; or progressive hemodynamic deterioration (mean blood pressure <35 mm Hg). The decision to offer extracorporeal membrane oxygenation was made by the attending physician and extracorporeal membrane oxygenation consulting team.
Our primary null hypothesis was that the use of extracorporeal membrane oxygenation would be the same in neonates treated with nitric oxide as in those not treated with nitric oxide. One of our secondary goals was to determine if inhaled nitric oxide reduced the risk of death and/or long-term complications (chronic lung disease and neurological handicaps). This secondary aim was a part of our original protocol and approved by each site's institutional review board and discussed at each of our investigator meetings. We now present data on follow-up to 1 year of life.
Follow-up
We scheduled all surviving infants to be seen at 6 and 12 months of age for a complete history and physical and neurological examination. We asked specific questions at each visit about medications they were taking, the number of hospitalizations since discharge and any neurodevelopmental problems the patient was having. Specific pulmonary medications we asked about were bronchodilators, diuretics, and use of supplemental oxygen. Any report of abnormal tone, developmental delay, cerebral palsy, persistent seizures, hearing or visual problems led to an assignment of an abnormal neurological examination label. When possible, a Bayley examination was performed. For patients who did not come to the clinic, we telephoned the patients' parents or guardians and asked the same questions.
Statistical analysis
Categorical variables were evaluated using two-tailed w 2 and Fisher's exact tests. Continuous variables were compared using two-tailed t-tests or the Kruskal-Wallis tests. Rank data were assessed using the two-tailed Kruskal-Wallis test.
RESULTS
Baseline characteristics
In all, 248 neonates were enrolled; 122 in the control group and 126 in the inhaled nitric oxide group. The baseline characteristics of the two treatment groups were similar as previously described. 1 The use of extracorporeal membrane oxygenation in neonates was lower in the inhaled nitric oxide group than in the control group (64% vs 38%, p<0.001).
Follow-up outcomes
Of the 248 neonates, 24 (10%) died before 1 year of age and all but one of these deaths occurred before hospital discharge. Of these 24 neonates died before discharge; most had congenital diaphragmatic hernia (12/23, 52%). Seven patients died with severe brain injury after treatment with extracorporeal membrane oxygenation; four had intracranial hemorrhage and three patients had signs of hypoxemic-ischemic injury (profound hypotonia, no spontaneous movement, and multiorgan failure). The cause of death was unclear in the patient who died at 10 months of life. There were no differences between the two groups in the causes of death or age at death (Table 1) . Of the 224 surviving infants, we were able to contact parents or guardians of 201 (90%), and 191 (85%) were seen in a follow-up clinic at least once during the first year of life. In the neonates followed to 1 year of life, the baseline characteristics were similar in both treatments except that the control patients were more often male and more often treated with extracorporeal membrane oxygenation than neonates who were assigned to the inhaled nitric oxide group.
In all 17 patients were on pulmonary medications at 1-year follow-up ( Table 2 ). All of the neonates who were classified as on pulmonary medications were prescribed bronchodilators. Neonates who were most often treated with pulmonary medications were those who had a congenital diaphragmatic hernia. Six of the 18 neonates with congenital diaphragmatic hernia who survived to 1 year of age were taking bronchodilators. In neonates without congenital diaphragmatic hernia, 21 of 171 were on bronchodilators and there was no difference in this event rate for neonates treated with inhaled nitric oxide compared to the control group.
The number of neonates reported to have an abnormal neurological examination or developmental delay was also similar in both groups (Table 2) . Of the 24 patients with a report of an abnormal neurological examination, four had findings consistent with severe cerebral palsy (cerebral atrophy on neurological imaging and/or markedly abnormal examination and severe developmental delay). Seven patients had mild trunk and lower extremity hypotonia and six were reported to have mild developmental delays without signs of severe neurological injury. Three patients had abnormal hearing tests, but otherwise were normal and two patients had problems with oral feedings. One patient had a history of seizures requiring continued treatment with phenobarbital and one patient had hydrocephalus requiring a ventricular peritoneal shunt. Only a small subsample of neonates received Bayley developmental testing, and in these neonates, there was no difference in neurodevelopmental outcome between those who received inhaled nitric oxide and those who did not (Table 2) . Hospitalization rates during the time between discharge and followup were not different between the two groups and most hospitalizations were related to pulmonary illness or surgical complications in neonates with congenital diaphragmatic hernia.
DISCUSSION
We previously reported that low-dose inhaled nitric oxide therapy reduces the use of extracorporeal membrane oxygenation in neonates with hypoxemic respiratory failure and persistent pulmonary hypertension. 1 In our hospital-based outcome data, we found an association between treatment with inhaled nitric oxide and improved pulmonary outcome; however, this improvement in outcome did not translate to a reduced need for outpatient treatment of lung disease or in reduced rehospitalization rates. The avoidance of extracorporeal membrane oxygenation was not associated with an increase in neurological injury. Only three reports have described the long-term outcome of a group of neonates who were treated with inhaled nitric oxide for persistent pulmonary hypertension. 3, 7, 8 Our data support these previous reports. Patients who are candidates for treatment with extracorporeal membrane oxygenation are critically ill and a significant proportion (>10%) has long-term pulmonary and neurodevelopmental problems. [8] [9] [10] [11] Like the Neonatal Inhaled Nitric Oxide Study Group (NiNOS), we found no evidence that being treated with inhaled nitric oxide and avoiding extracorporeal membrane oxygenation was associated with any increase in adverse pulmonary or neurological injury.
We should be cautious in concluding that our data demonstrate that inhaled nitric oxide is as safe as placebo. None of the published studies were adequately powered to discern small but meaningful differences in pulmonary or neurodevelopmental outcome. In addition, follow-up to 1 year of age is not adequate for the assessment of future school performance. It is important to note that only extracorporeal membrane oxygenation has been shown to improve intact survival in critically ill term neonates. 12 Monitoring the outcomes of neonates treated with inhaled nitric oxide remains essential.
